William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties
Incyte Corporation (NASDAQ:INCY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 30,739,953 | $1,861,304,154 | +1% | 20.6% |
| 2. | AQR Capital Management Cliff Asness | 6,736,169 | $405,786,825 | +93% | 0.42% |
| 3. | Renaissance Technologies Jim Simons | 3,708,732 | $224,563,723 | -10% | 0.34% |
| 4. | Armistice Capital Steven Boyd | 1,671,463 | $101,207,085 | -6% | 1.52% |
| 5. | GLG Partners Noam Gottesman | 1,054,427 | $63,845,555 | +45% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | $12,887,302.92 | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | $1,062,243.06 | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | $73,176.91 | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | $6,044.11 | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | $1,805,125.51 | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.15 | 10,903 | $743,039.45 | 39,744 | 2025-07-03 | Filing | |
| $68.61 | 599 | $41,097.39 | 26,504 | 2025-07-02 | Filing | |
| $68.15 | 5,935 | $404,470.25 | 37,701 | 2025-07-03 | Filing | |
| $68.16 | 2,682 | $182,805.12 | 43,636 | 2025-07-03 | Filing | |
| $68.00 | 1,795 | $122,060.00 | 26,504 | 2025-06-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 611,294 | $41,629,120 | 0.05% | |
| 2. | 82,835 | $5,670,030 | 0.01% | |
| 3. | 39,271 | $2,674,355 | 0.02% | |
| 4. | 38,000 | $2,587,800 | 0.1% | |
| 5. | 31,404 | $2,138,612 | 0.02% |
News See All
10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio
Ray Dalio began his investing journey at just 12 years old and went on to gain experience at institutions such as the New York Stock Exchange, Dominick & Dominick LLC, and Shearson Hayden Stone.
Jim Cramer Highlighted the Top 10 S&P 500 Winners of the Day
“For much of the tremendous run over the past decade, critics love to point out that most of our gains were coming from a small cadre of tech stocks… Over and over again, as the market roared higher...
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now.
8 Cheap Beginner Stocks to Buy Right Now
Talk of a slowing economy has once again gained popularity within economic circles.
Morgan Stanley Maintains Hold Rating on Incyte (INCY) Stock
On June 4, Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte Corporation (NASDAQ:INCY) with a price target of $68.00.
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying
The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two years of weak performance, the healthcare sector kicked off on a strong note in 2025.
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript
Operator: On today's call, I am joined by Herve Hoppenot, Pablo Cagnoni, and Christiana Stamoulis, who will deliver our prepared remarks.
Billionaire Hedge Funds
